[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CO4940465A1 - Sal mesilato trihidrato de 5-(2-(4-(1,2-benzoisotiazol-3- il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona - Google Patents

Sal mesilato trihidrato de 5-(2-(4-(1,2-benzoisotiazol-3- il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona

Info

Publication number
CO4940465A1
CO4940465A1 CO97022512A CO97022512A CO4940465A1 CO 4940465 A1 CO4940465 A1 CO 4940465A1 CO 97022512 A CO97022512 A CO 97022512A CO 97022512 A CO97022512 A CO 97022512A CO 4940465 A1 CO4940465 A1 CO 4940465A1
Authority
CO
Colombia
Prior art keywords
dihydro
benzoisotiazol
piperazinil
etil
ona
Prior art date
Application number
CO97022512A
Other languages
English (en)
Inventor
Frank R Bush
A Rose Carol
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CO4940465A1 publication Critical patent/CO4940465A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a la sal mesilato trihidrato de5-(2-(4-(1,2-benzoisotiazol-3-il)-1-piperazinil) etil)-6-cloro-1,3-dihidro-2H-indol-2-ona, a composiciones farmacéuticas que contienen dicha sal mesilato trihidrato y a procedimientos de uso de dicha sal mesilato trihidrato para tratar trastornos psicóticos.
CO97022512A 1996-05-07 1997-04-28 Sal mesilato trihidrato de 5-(2-(4-(1,2-benzoisotiazol-3- il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona CO4940465A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1653796P 1996-05-07 1996-05-07

Publications (1)

Publication Number Publication Date
CO4940465A1 true CO4940465A1 (es) 2000-07-24

Family

ID=21777622

Family Applications (1)

Application Number Title Priority Date Filing Date
CO97022512A CO4940465A1 (es) 1996-05-07 1997-04-28 Sal mesilato trihidrato de 5-(2-(4-(1,2-benzoisotiazol-3- il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona

Country Status (46)

Country Link
US (1) US6110918A (es)
EP (1) EP0904273B1 (es)
JP (1) JP3102896B2 (es)
KR (1) KR100333214B1 (es)
CN (1) CN1092658C (es)
AP (1) AP838A (es)
AR (1) AR007003A1 (es)
AT (1) ATE236902T1 (es)
AU (1) AU730856C (es)
BG (1) BG63601B1 (es)
BR (1) BR9708932A (es)
CA (1) CA2252895C (es)
CO (1) CO4940465A1 (es)
CZ (1) CZ289216B6 (es)
DE (1) DE69720719T2 (es)
DK (1) DK0904273T3 (es)
DZ (1) DZ2221A1 (es)
EA (1) EA001180B1 (es)
EG (1) EG24401A (es)
ES (1) ES2192264T3 (es)
GT (1) GT199700042A (es)
HK (1) HK1017893A1 (es)
HN (1) HN1997000040A (es)
HR (1) HRP970235B1 (es)
HU (1) HU229057B1 (es)
ID (1) ID17504A (es)
IL (1) IL126590A (es)
IS (1) IS2301B (es)
MA (1) MA26427A1 (es)
ME (1) ME00901B (es)
MY (1) MY128051A (es)
NO (1) NO312513B1 (es)
NZ (2) NZ508303A (es)
OA (1) OA10908A (es)
PL (1) PL188164B1 (es)
PT (1) PT904273E (es)
SI (1) SI0904273T1 (es)
SK (1) SK282674B6 (es)
TN (1) TNSN97073A1 (es)
TR (1) TR199802241T2 (es)
TW (1) TW427989B (es)
UA (1) UA47467C2 (es)
UY (1) UY24543A1 (es)
WO (1) WO1997042190A1 (es)
YU (1) YU49398B (es)
ZA (1) ZA973875B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
DK0985414T3 (da) * 1998-05-26 2003-12-29 Pfizer Prod Inc Lægemiddel til behandling af glaukome og iskæmisk retinopati
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
TR200201617T2 (tr) 1999-12-23 2002-10-21 Pfizer Products Inc. Kuvvetlendirilmiş ilaç konsantrasyonları sağlayan farmasötik kompozisyonlar
SI1468686T1 (sl) * 2000-06-02 2007-04-30 Pfizer Prod Inc S-metil-dihidro-ziprazidon za zdravljenje psihiatricnih motenj
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
WO2004050655A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride
US7488729B2 (en) 2002-12-04 2009-02-10 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
EP1626722A1 (en) * 2003-05-16 2006-02-22 Pfizer Products Inc. Method for enhancing cognition using ziprasidone
WO2004100955A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Anxiety treatments with ziprasidone
EP1633360A1 (en) * 2003-05-16 2006-03-15 Pfizer Products Incorporated Treatment of psychotic and depressive disorders
CA2528100A1 (en) * 2003-06-03 2005-04-21 Teva Pharmaceutical Industries Ltd Polymorphic forms of ziprasidone hcl and processes for their preparation
KR20090080143A (ko) * 2003-09-02 2009-07-23 화이자 프로덕츠 인크. 지프라시돈의 지속 방출형 투여 형태
WO2005040160A2 (en) * 2003-10-24 2005-05-06 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
EP1592688A2 (en) 2003-12-18 2005-11-09 Teva Pharmaceutical Industries Ltd. Polymorphic form b2 of ziprasidone base
CA2552126A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Ziprasidone formulations
WO2005085240A2 (en) * 2004-02-27 2005-09-15 Ranbaxy Laboratories Limited Process for the preparation of ziprasidone
WO2006026426A2 (en) * 2004-08-27 2006-03-09 University Of Kentucky Research Foundation Amyloid peptide inactivating enzyme to treat alzheimer’s disease peripherally
ES2250001B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
JP5324098B2 (ja) * 2004-11-16 2013-10-23 アルケルメス ファーマ アイルランド リミテッド 注射可能なナノ粒子のオランザピン製剤
CA2593497A1 (en) * 2005-02-11 2006-08-17 Judith Aronhime Amorphous ziprasidone mesylate
CA2598288A1 (en) * 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2599391A1 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
WO2006099452A1 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Anhydrous ziprasidone mesylate and a process for its preparation
MX2009011681A (es) * 2007-05-18 2009-11-10 Scidose Llc Formulaciones de ziprasidona.
KR100948126B1 (ko) * 2007-12-10 2010-03-18 씨제이제일제당 (주) 결정형의 지프라시돈 술폰산염, 그 제조방법, 및 그것를포함하는 약제학적 조성물
CN102234273B (zh) * 2010-04-21 2015-08-05 上海医药工业研究院 甲磺酸齐拉西酮半水合物及其制备方法
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one

Also Published As

Publication number Publication date
NZ332219A (en) 2005-02-25
JP3102896B2 (ja) 2000-10-23
PL188164B1 (pl) 2004-12-31
EG24401A (en) 2009-04-29
YU17397A (sh) 2000-10-30
DE69720719T2 (de) 2003-11-06
EA199800909A1 (ru) 1999-04-29
OA10908A (en) 2001-10-26
HUP9902808A2 (hu) 2000-03-28
JPH11509865A (ja) 1999-08-31
NZ508303A (en) 2001-07-27
DK0904273T3 (da) 2003-07-07
NO985193L (no) 1998-11-06
YU49398B (sh) 2005-11-28
MA26427A1 (fr) 2004-12-20
SK150598A3 (en) 2000-03-13
IL126590A0 (en) 1999-08-17
UY24543A1 (es) 2000-09-29
CN1092658C (zh) 2002-10-16
EP0904273B1 (en) 2003-04-09
SI0904273T1 (en) 2003-08-31
HU229057B1 (en) 2013-07-29
TW427989B (en) 2001-04-01
EA001180B1 (ru) 2000-10-30
EP0904273A1 (en) 1999-03-31
DE69720719D1 (de) 2003-05-15
AP838A (en) 2000-05-03
BG63601B1 (bg) 2002-06-28
UA47467C2 (uk) 2002-07-15
WO1997042190A1 (en) 1997-11-13
MY128051A (en) 2007-01-31
ES2192264T3 (es) 2003-10-01
HN1997000040A (es) 1997-06-05
IS2301B (is) 2007-10-15
HRP970235A2 (en) 1998-06-30
IS4878A (is) 1998-10-23
ME00901B (me) 2005-11-28
AR007003A1 (es) 1999-10-13
TNSN97073A1 (fr) 2005-03-15
CN1216990A (zh) 1999-05-19
KR20000010822A (ko) 2000-02-25
PL329880A1 (en) 1999-04-12
AP9700978A0 (en) 1997-07-31
ZA973875B (en) 1998-11-06
BG102893A (en) 1999-09-30
PT904273E (pt) 2003-06-30
US6110918A (en) 2000-08-29
CZ349498A3 (cs) 1999-09-15
AU730856B2 (en) 2001-03-15
ID17504A (id) 1998-01-08
IL126590A (en) 2001-11-25
CA2252895A1 (en) 1997-11-13
KR100333214B1 (ko) 2002-06-20
CZ289216B6 (cs) 2001-12-12
DZ2221A1 (fr) 2002-12-03
HUP9902808A3 (en) 2000-04-28
AU730856C (en) 2001-11-15
CA2252895C (en) 2002-08-20
GT199700042A (es) 1998-10-02
HRP970235B1 (en) 2002-08-31
AU1936897A (en) 1997-11-26
HK1017893A1 (en) 1999-12-03
SK282674B6 (sk) 2002-11-06
NO985193D0 (no) 1998-11-06
BR9708932A (pt) 1999-08-03
NO312513B1 (no) 2002-05-21
TR199802241T2 (es) 1999-02-22
ATE236902T1 (de) 2003-04-15

Similar Documents

Publication Publication Date Title
CO4940465A1 (es) Sal mesilato trihidrato de 5-(2-(4-(1,2-benzoisotiazol-3- il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona
MY119997A (en) Mesylate dihydrate salts of 5-(2-(4-(1, 2-benzisothiazol-3-yl) -1-piperazinyl)-6-chloro-1, 3- dihydro-2h-indol-2-one
RU93043528A (ru) Моногидрат 5-(2-(4-(1,2-бензотиазол-3-ил)-1-пиперазинил)этил)-6-хлор-1,3-дигидро-2н-индол-2-он хлоргидрата, способ его получения, фармацевтическая композиция, способ лечения
ATE219064T1 (de) Piperazinderivative als tachykinin antagonisten
ES2172498T3 (es) Composicion de tratamiento o de maquillaje que contiene fibras y un organopolisiloxano hidrofilo.
BR9810829B1 (pt) composto heterocìclico, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica.
BR9909486A (pt) Compostos calcilìticos
BR0017157A (pt) Derivados de 6-hidroxi-indazol para o tratamento de glaucoma
FI973221A (fi) 1-aryyli-2-asyyliammo-etaaniyhdisteitä ja niiden käyttö neurokiniiniantagonisteina, erityisesti neurokiniini 1 antagonisteina
BR9901058A (pt) N-cail e n-aroil aralquil amidas.
DK0978284T3 (da) Anvendelse af 15-keto-prostaglandin-E-forbindelser som endothelinantagonister
PT790236E (pt) Pro-farmacos de 5-(2-(4-(1,2-benzisotiazol-3-il)-1-piperazinil)-etil-6-cloro-1,3-di-hidro-2h-indol-2-ona
NO20000519L (no) 2-acylaminopropanaminer som takykininreseptorantagonister
ATE254122T1 (de) Indolderivate als 5-ht1b und 5-ht1d agonisten
MX9205186A (es) Derivados de 4-[4-[4-(4-hidroxifenil)-1-piperazinil]-fenil]-5-metil-3h-1,2,4-triazo l-3-ona
ECSP972089A (es) Sal mesilato trihidrato de 5-[2-[4(1,2-benzoisotiazol-3-il]-1-piperazinil)etil]-6-cloro- 1,3- dihidro- 2h- inddol - 2 - ona
ATE217619T1 (de) Endothelin-rezeptor-antagonisten
MX9704035A (es) 1,1-dioxidos de 2-(fosfiniloximetil)-1,2,5-tiadiazolidin-3-ona substituidos y composiciones y metodo de uso de los mismos.
FI972307A0 (fi) 2-(2,3,5,6-tetrafluori-4-pyridyyli)-1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
ES2175424T3 (es) Sal de metansulfonato de una arilpiperazina derivada de triptamina y sus solvatos para uso farmaceutico.
ECSP972096A (es) Sales metanosulfanato de 5-[2-[4-[1,2-benzoisotiazol-3- [il] -1 -piperaziniletil]-6-cloro-1,3 2h - indol - 2-ona dihidratas
MY109504A (en) Monohydrate of 5-(2-(4-(1,2 benzisothiazol-3-yl)-1- piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2- one hydrochloride